Warning: The NCBI web site requires JavaScript to function. more...
Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study.
Link A, Girndt M, Selejan S, Rbah R, Böhm M.
Crit Care. 2008;12(4):R111. Epub 2008 Aug 29.
Related citations
Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?
Storm C, Jörres A.
Crit Care. 2008;12(6):193. Epub 2008 Nov 24.
High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Walters DL, Ray MJ, Wood P, Perrin EJ, Bett JH, Aroney CN.
Eur J Clin Invest. 2010 Feb;40(2):139-47. Epub 2009 Dec 21.
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, Todaro D, Giammarinaro M, Leone AM, Niccoli G, Andreotti F, Mazzari MA, Schiavoni G, Crea F.
J Cardiovasc Med (Hagerstown). 2009 Mar;10(3):245-51.
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Ivandic BT, Kurz K, Keck F, Staritz P, Lehrke S, Katus HA, Giannitsis E.
Thromb Haemost. 2008 Oct;100(4):648-54.
Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Straub A, Azevedo R, Beierlein W, Wendel HP, Dietz K, Ziemer G.
Thorac Cardiovasc Surg. 2006 Apr;54(3):162-7.
Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.
Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA.
Intensive Care Med. 2007 Sep;33(9):1563-70. Epub 2007 Jun 27.
Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
Koster A, Fischer T, Gruendel M, Mappes A, Kuebler WM, Bauer M, Kuppe H.
J Cardiothorac Vasc Anesth. 2003 Apr;17(2):171-5.
Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.
Birnbaum J, Spies CD, Klotz E, Hein OV, Morgera S, Schink T, Ziemer S, Grund MS, Saalmann R, Kox WJ, Lehmann C.
Ren Fail. 2007;29(3):271-7.
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Tavano D, Visconti G, D'Andrea D, Focaccio A, Golia B, Librera M, Caccavale M, Ricciarelli B, Briguori C.
Am J Cardiol. 2009 Nov 1;104(9):1222-8.
Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V, Malinin A, Pokov A, Arora U, Atar D, Angiolillo D.
Thromb Res. 2007;119(2):175-81. Epub 2006 Mar 20.
Argatroban for anticoagulation in continuous renal replacement therapy.
Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H.
Crit Care Med. 2009 Jan;37(1):105-10.
Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.
Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T.
J Crit Care. 2005 Jun;20(2):155-61.
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter.
Arcangeli A, Rocca B, Salvatori G, Ciancia M, De Cristofaro R, Antonelli M.
Thromb Res. 2010 Jul;126(1):24-31. Epub 2010 Feb 24.
Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.
Hiramatsu Y, Gikakis N, Anderson HL 3rd, Gorman JH 3rd, Marcinkiewicz C, Gould RJ, Niewiarowski S, Edmunds LH Jr.
J Thorac Cardiovasc Surg. 1997 Jan;113(1):182-93.
Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy.
Vitale C, Verdecchia C, Bagnis C, Ganzaroli M, Giorcelli G, Marangella M.
J Nephrol. 2008 Mar-Apr;21(2):205-12.
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation.
Ray MJ, Juneja M, Bett N, Walters DL.
EuroIntervention. 2009 Aug;5(3):330-5.
Platelet loss across the hemofilter during continuous hemofiltration.
Mulder J, Tan HK, Bellomo R, Silvester W.
Int J Artif Organs. 2003 Oct;26(10):906-12.
Predictive value of RIFLE classification on prognosis of critically ill patients with acute kidney injury treated with continuous renal replacement therapy.
Li WX, Chen HD, Wang XW, Zhao S, Chen XK, Zheng Y, Song Y.
Chin Med J (Engl). 2009 May 5;122(9):1020-5.
Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial.
Lins RL, Elseviers MM, Van der Niepen P, Hoste E, Malbrain ML, Damas P, Devriendt J; SHARF investigators.
Nephrol Dial Transplant. 2009 Feb;24(2):512-8. Epub 2008 Oct 14.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on